半乳糖凝集素治療公司
US ˙ NasdaqCM ˙ US3632252025

SecurityGALT / Galectin Therapeutics Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership10,151 shares
Latest Disclosed Value $ 21,418
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 75.00% decrease in ownership of GALT / Galectin Therapeutics Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 10,151 shares of Galectin Therapeutics Inc. (US:GALT) valued at $21,419 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 40,602 shares of Galectin Therapeutics Inc.. This represents a change in shares of -75.00% during the quarter. The current value of the position is $23,652 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Galectin Therapeutics EC US3632252025 10,151 -30,451 -75.00 21 -57.14 0.0005
2025-05-28 2025-03-31 NP Galectin Therapeutics EC US3632252025 40,602 0 0.00 50 -5.77 0.0012
2025-02-25 2024-12-31 NP Galectin Therapeutics EC US3632252025 40,602 0 0.00 52 -53.15 0.0011
2024-11-26 2024-09-30 NP Galectin Therapeutics EC US3632252025 40,602 -31,043 -43.33 112 -28.39 0.0021
2021-05-27 2021-03-31 NP Galectin Therapeutics EC US3632252025 71,645 0 0.00 155 -3.12 0.0035
2021-02-25 2020-12-31 NP Galectin Therapeutics EC US3632252025 71,645 0 0.00 160 -16.23 0.0041
2020-11-25 2020-09-30 NP Galectin Therapeutics EC US3632252025 71,645 0 0.00 191 -12.79 0.0061
2020-08-27 2020-06-30 NP Galectin Therapeutics EC US3632252025 71,645 0 0.00 219 56.43 0.0072
2020-06-01 2020-03-31 NP Galectin Therapeutics EC US3632252025 71,645 0 0.00 140 -31.37 0.0057
2020-02-27 2019-12-31 NP Galectin Therapeutics EC 363225202 71,645 23,496 48.80 205 15.91 0.0062
2019-11-27 2019-09-30 NP Galectin Therapeutics EC US3632252025 48,149 48,149 177 0.0058
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.